What does CUSIP 501575104 represent in this 13F holders report?

CUSIP 501575104 is the security identifier for KYMR - Kymera Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held KYMR - Kymera Therapeutics, Inc. - Common Stock in Q2 2022?

99 institutional investors reported KYMR - Kymera Therapeutics, Inc. - Common Stock for Q2 2022. Use the holders table for investor-level position and value details.

Kymera Therapeutics, Inc. - Common Stock (KYMR)

CUSIP: 501575104

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock
Shares outstanding: 80,235,145
Total 13F shares: 49,442,050
Share change: +3,794,578
Total reported value: $973,574,555
Put/Call ratio: 0%
Price per share: $19.69
Number of holders: 99
Value change: +$16,502,218
Number of buys: 54
Number of sells: 64

Quarterly Holders Quick Answers

What is CUSIP 501575104?
CUSIP 501575104 identifies KYMR - Kymera Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 501575104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of KYMR - Kymera Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Atlas Venture Life Science Advisors, LLC	13F	Company	8.6%	6,875,698	$290,980,000	—	31 Mar 2022	13F
ATLAS VENTURE ASSOCIATES X, L.P.	3/4/5	10%+ Owner	— class O/S missing	5,763,012	$173,161,222	—	11 Aug 2021	3/4/5
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	4.9%	3,895,205	$164,845,000	—	31 Mar 2022	13F
BVF INC/IL	13F	Company	4.5%	3,586,658	$151,787,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	4.3%	3,419,084	$144,698,000	—	31 Mar 2022	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	4%	3,225,749	$136,514,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	3.5%	2,837,725	$120,092,000	—	31 Mar 2022	13F
Redmile Group, LLC	13F	Company	3.3%	2,615,030	$110,668,000	—	31 Mar 2022	13F
BAKER BROS. ADVISORS LP	13F	Company	3%	2,384,742	$100,922,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	2.6%	2,094,561	$88,642,000	—	31 Mar 2022	13F
FMR LLC	13F	Company	2.4%	1,923,889	$81,419,000	—	31 Mar 2022	13F
Artal Group S.A.	13F	Company	1.2%	1,000,000	$42,320,000	—	31 Mar 2022	13F
Avoro Capital Advisors LLC	13F	Company	1%	816,500	$34,554,000	—	31 Mar 2022	13F
Rock Springs Capital Management LP	13F	Company	0.94%	755,875	$31,989,000	—	31 Mar 2022	13F
Bank of New York Mellon Corp	13F	Company	0.86%	686,194	$29,041,000	—	31 Mar 2022	13F
Point72 Asset Management, L.P.	13F	Company	0.81%	652,800	$27,626,000	—	31 Mar 2022	13F
PICTET ASSET MANAGEMENT SA	13F	Company	0.81%	646,075	$27,342,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.78%	623,770	$26,397,000	—	31 Mar 2022	13F
Deer Management Co. LLC	13F	Company	0.77%	615,895	$26,065,000	—	31 Mar 2022	13F
AJU IB Investment Co., Ltd.	13F	Company	0.57%	457,059	$19,343,000	—	31 Mar 2022	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.54%	430,243	$18,207,883	—	31 Mar 2022	13F
S.c.a. Candriam	13F	Individual	0.52%	414,713	$17,550,000	—	31 Mar 2022	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.46%	368,061	$15,576,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.4%	319,865	$13,536,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.32%	255,277	$10,804,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.3%	243,926	$10,323,000	—	31 Mar 2022	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.3%	237,731	$10,060,000	—	31 Mar 2022	13F
WASATCH ADVISORS LP	13F	Company	0.3%	237,357	$10,045,000	—	31 Mar 2022	13F
Paradigm Biocapital Advisors LP	13F	Company	0.28%	227,034	$9,608,000	—	31 Mar 2022	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.27%	212,960	$9,012,000	—	31 Mar 2022	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.25%	199,244	$8,432,000	—	31 Mar 2022	13F
CLOUGH CAPITAL PARTNERS L P	13F	Company	0.23%	185,700	$7,859,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0.23%	185,474	$7,850,000	—	31 Mar 2022	13F
Alyeska Investment Group, L.P.	13F	Company	0.23%	183,750	$7,776,000	—	31 Mar 2022	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.22%	180,000	$7,618,000	—	31 Mar 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.22%	172,800	$7,313,000	—	31 Mar 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.2%	163,475	$6,918,000	—	31 Mar 2022	13F
NORGES BANK	13F	Company	0.17%	138,691	$5,869,403	—	31 Mar 2022	13F
UBS Group AG	13F	Company	0.17%	136,090	$5,759,000	—	31 Mar 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.16%	129,237	$5,470,000	—	31 Mar 2022	13F
Rafferty Asset Management, LLC	13F	Company	0.15%	124,128	$5,253,000	—	31 Mar 2022	13F
GILDER GAGNON HOWE & CO LLC	13F	Company	0.14%	114,506	$4,846,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.13%	107,232	$4,354,000	—	31 Mar 2022	13F
TD ASSET MANAGEMENT INC	13F	Company	0.1%	83,462	$3,532,000	—	31 Mar 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.09%	74,658	$3,160,000	—	31 Mar 2022	13F
Swiss National Bank	13F	Company	0.08%	66,900	$2,831,000	—	31 Mar 2022	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.08%	61,614	$2,608,000	—	31 Mar 2022	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.08%	61,413	$2,561,070	—	31 Mar 2022	13F
Ensign Peak Advisors, Inc	13F	Company	0.07%	59,280	$2,509,000	—	31 Mar 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.07%	56,324	$2,384,000	—	31 Mar 2022	13F

Institutional Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q2 2022

As of 30 Jun 2022, Kymera Therapeutics, Inc. - Common Stock (KYMR) was held by 99 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 49,442,050 shares. The largest 10 holders included Atlas Venture Life Science Advisors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, BVF INC/IL, STATE STREET CORP, BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, BlackRock Inc., Redmile Group, LLC, and Avoro Capital Advisors LLC. This page lists 99 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

124

Q2 2022 holders

Holder diff

-25

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.